<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272086</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 19-1807</org_study_id>
    <nct_id>NCT04272086</nct_id>
  </id_info>
  <brief_title>Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy</brief_title>
  <official_title>Effect of Transversus Abdominal Plane Block Using Liposomal Bupivacaine Versus Standard Bupivacaine for Open Myomectomy: A Prospective Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team will be randomizing patients presenting for open myomectomy to either received
      transversus abdominal plane blocks with either liposomal bupivacaine or standard bupivacaine.
      The study team will be analyzing the impact of local anesthetic on opiate consumption as the
      investigator's primary endpoint with other secondary endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consent, patients will be randomized to either liposomal bupivacaine Transversus
      Abdominal Plane (TAP) vs standard bupivacaine TAP. Blocks will occur post induction and pre
      incision. Only the block team (not the anesthesia team nor the care team) will be unblinded
      and they will not have any impact on the data collection. The entire care team and the
      patient will be blinded. A standardized anesthetic regimen will be employed followed by a
      prescriptive post-operative pain management plan aimed at enhanced recovery. Patients will be
      followed for up to 96 hours and asked about their opiate consumption, pain scores, side
      effects, and recovery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomized control trial with intervention arm as liposomal bupivacaine tap and intervention as standard bupivacaine tap</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The only people who will be unblinded are the members of the block team, who are not members of the care team nor the study team. They will open the envelopes, draw up the medications and cover the syringes with opaque paper such that no one can tell the contents.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine Equivalents at 72 Hours</measure>
    <time_frame>72 hours</time_frame>
    <description>Total cumulative opiates consumed converted to morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalents at 96 Hours</measure>
    <time_frame>96 hours</time_frame>
    <description>Total cumulative opiates consumed converted to morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalents at 48 Hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Total cumulative opiates consumed converted to morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opiate Sparing Criteria at 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>Composite score of minimal opiate dose and additionally scores of 0 on questions 2,3,4,5,6 on OBAS scoring scale.
Overall Benefit of Analgesic Score (OBAS) scoring scale -total scale from 0-20, low score indicates high benefit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>15 question quality of recovery scale, full scale from 0-150, with lower score indicating better recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery at 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>15 question quality of recovery scale, full scale from 0-150, with lower score indicating better recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve pain scale at 96 hours</measure>
    <time_frame>96 hours</time_frame>
    <description>Sum of pain scores at 24, 48, 72, and 96 hours. Pain scale from 0-10, with higher score indicating worst pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Fibroid Uterus</condition>
  <arm_group>
    <arm_group_label>Bupivacaine TAP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine TAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>0.25%</description>
    <arm_group_label>Bupivacaine TAP</arm_group_label>
    <arm_group_label>Liposomal bupivacaine TAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine liposome</intervention_name>
    <description>10mL</description>
    <arm_group_label>Liposomal bupivacaine TAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>10ml</description>
    <arm_group_label>Bupivacaine TAP</arm_group_label>
    <arm_group_label>Liposomal bupivacaine TAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not pregnant

          -  Weight over 50kg presenting for open myomectomy

          -  No history of allergy to any study medication

          -  No history of malignant ventricular dysrhythmia, epilepsy, seizure disorder, or
             chronic pain syndrome other than pain from myomas

          -  No history of drug or alcohol use or abuse disorder or pre-existing liver disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women have uterine fibroids</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Katz, MD</last_name>
    <phone>212-241-7475</phone>
    <email>daniel.katz@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Leader</last_name>
    <phone>212-241-7475</phone>
    <email>james.leader@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Katz, MD</last_name>
      <phone>212-241-7475</phone>
      <email>daniel.katz@mountsinai.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Daniel Katz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fibroid uterus</keyword>
  <keyword>Myomectomy</keyword>
  <keyword>Abdominal myomectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

